Navigation Links
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
Date:4/29/2009

- Primary Endpoint met With a Significant Reduction in Relapse Rate

- Secondary Endpoints met Including MRI Measures, Proportion of Patients Relapse-Free and Disability Progression

- Submission for Registration of Cladribine Tablets Planned for mid-2009

SEATTLE and GENEVA, April 30 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, announced today detailed results of the two-year (96-week) placebo-controlled CLARITY(1) Phase III trial using Cladribine Tablets (Merck Serono's proprietary investigational oral formulation of cladribine) to treat patients with relapsing-remitting multiple sclerosis (MS). The results of the pivotal trial show that annual short-course treatment with Cladribine Tablets led to a significant reduction in the rate of clinical relapses, disability progression and brain lesions, as well as a significant increase in the proportion of patients who remained relapse-free. The data were presented today for the first time, as a late-breaking oral presentation at the 61st Annual Meeting of the American Academy of Neurology (AAN) in Seattle, WA.

"All primary and secondary endpoints of the CLARITY study were statistically significant and demonstrate that annual short-course treatment with Cladribine Tablets in this study was effective across multiple important clinical and MRI efficacy measures," said Dr. Gavin Giovannoni, principal investigator of the study, Institute of Cell and Molecular Science, Barts and The London School of Medicine and Dentistry, London, United Kingdom.

"We are very pleased with the successful outcome of the CLARITY study," said Elmar Schnee, President of Merck Serono. "This is an exciting development in multiple sclerosis clinical research, and represents an important step towards delivering an oral therapy to people living with this condition."

The results from both Cladribine Tablets treatment groups in the study d
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
4. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
9. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
10. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
11. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... August 3, 2015 BiondVax Pharmaceuticals Ltd. ... analysis of results from a study which demonstrates that BiondVax,s ... trial which took place in 2012, provided participants with increased ... time of the study- in particular the current newly emerged ... the United States in 2015. ...
(Date:8/3/2015)... SAN DIEGO , Aug. 3, 2015  Sorrento ... that it has entered into an exclusive licensing agreement ... or biobetter antibodies from Mabtech Limited, a holding company ... China . Under the ... these 4 monoclonal antibodies (mAbs) for the North American, ...
(Date:7/31/2015)... July 31, 2015  Physicians and payers alone ... biopharmaceutical market. Patients are better informed and getting ... switching therapies. This shift in power is reshaping ... toward patient-focused marketing. As part of ... learned it,s important to educate, communicate and engage ...
Breaking Medicine Technology:Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 2Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 3Sorrento In-Licenses Four Late-Stage Clinical Biobetter and Biosimilar Antibodies 4Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2
... N.J., July 11, 2011 MonoSol Rx, a ... PharmFilm® technology platform, in collaboration with APR Applied ... that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble ... partners.  The Company made the strategic decision to ...
... YORK, July 11, 2011 Reportlinker.com announces ... available in its catalogue: ... approval brings lessons and hope to market ... To order this report: ...
Cached Medicine Technology:MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 2MonoSol Rx Announces Availability of Zuplenz® Oral Soluble Film for Licensing to New Commercialization Partners 3
(Date:8/3/2015)... ... August 03, 2015 , ... Representatives with Health ... on its website. , “Our ‘Ask a Nutritionist’ feature on our website is a ... healthily,” said Liza Brisk, nutritionist and spokeswoman for Health Food Grocers. , Health Food ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data ... IT to create efficiencies in healthcare information exchange, announced the release of its findings ... and Human Services (HHS) Secretary, WEDI shared survey results and recommendations ...
(Date:8/3/2015)... ... ... They know every second counts. And when it comes to stroke, the ... best care in the nation. For the past two months, the stroke team led ... time in the country. During the months of June and July, it took the ...
(Date:8/3/2015)... ... 03, 2015 , ... BESLER Consulting today announced the firm ... The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and creative ... of their Readmissions Analytics product was selected as one of four finalists in ...
(Date:8/3/2015)... ... August 03, 2015 , ... Novation, the nation’s largest ... pharmacogenetic lab testing and precision medicine solutions that can help pharmacists and other ... more than 8.6 million adverse drug events are reported in the U.S. ...
Breaking Medicine News(10 mins):Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 2Health News:Health Food Grocers Launches "Ask a Nutritionist" Service 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 2Health News:Providence St. Vincent Stroke Care Recognized Among Best in the Country 3Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 2Health News:Novation Awards Genelex First Group Purchasing Agreement for Pharmacogenetic Testing and Precision Medicine Software 3
... threeat to the globe as 95% of the AIDS ... General Assembly Special Session on HIV/AIDS, physicians demanded to ... would cater the AIDS victims in developing countries. ... (commonly known as Medicines Sans Frontieres, or MSF), MSF ...
... herbal product ginseng root has a number of psychological ... boosting mood performance. But researchers have found no psychological ... PhD, associate professor and co-director of the sport and ... Corvallis, Oregon and his colleague, Hermann Engles, PhD, conducted ...
... inherited disease of the nervous system due to the ... such as involuntary movements and balance problems and later ... well. ,All these days, until now, it was ... form of the protein 'huntingtin' which is responsible for ...
... bacteria known as E. coli 0157:H7 causes some of ... adults. Infections with this organism are often caused by ... to treat children with E. coli bacterial infection increases ... ,"Our data suggests that antibiotics are not only ...
... go in for strategic alliances among themselves to ... and precluding cut-throat competition which would be detrimental ... the Commerce Secretary, Mr. Prabir Sengupta, at the ... Pharmaceuticals and Cosmetics Export Promotion Council here on ...
... its true , this salient disclosure revealed its truth when ... Dr. Fernando D. Martinez ,According to Dr.Fernando D.Martinez and collegues ... between 6 and 11 years of age have a sevenfold ... any such associated risk of asthma even if they are ...
Cached Medicine News:Health News:Pharma cos must forge Strategic alliances 2
... 1575 immunowash microplate washer ... needle position to perform ... maximize wash efficiency. This ... choice of wash that ...
... LMW Automated Microplate ... choice for any laboratory. ... sensor allows a precise ... residual volume, digitally controlled ...
... ELx50 is a fast and versatile automated strip ... manifold. It is a self contained and programmable ... fluidic delivery from the gentle dripping of a ... pressure delivery systems. ELx50/12V processes 1 x 12 ...
... The Microplate washer MP-1200 is ... microplate washing system. Its internal micropumps ... and to discharge from all types ... microplate to be washed in rows ...
Medicine Products: